Wegovy — proven for years, properly supervised.
Wegovy (semaglutide) is a once-weekly injection licensed in the UK for weight management. It was the first GLP-1 receptor agonist licensed for weight loss, and has the broadest clinical evidence base of any treatment in this class. Prescribed only after a full clinical review and a video consultation with our specialist weight-loss prescriber.
The original GLP-1 for weight loss.
Semaglutide is the active ingredient in Wegovy. It is a GLP-1 receptor agonist — it mimics the action of a hormone called glucagon-like peptide-1 that your gut naturally releases after you eat. GLP-1 plays a central role in how you feel full, how quickly food leaves your stomach, and how your body regulates blood sugar.
By activating the GLP-1 receptor more strongly and for longer than the body's own signal, Wegovy reduces appetite, slows gastric emptying, and improves blood sugar control. The effect is that you feel fuller sooner and for longer after eating. Like all weight-loss medications, it works alongside dietary and activity changes — not as a replacement for them.
Wegovy was the first medication in this class to be licensed by the MHRA specifically for weight management in adults with obesity, or with overweight plus a weight-related health condition. It's a prescription-only medicine and must be prescribed by a UK-registered clinician after proper assessment.
What you might experience.
Most people experience some side effects, especially when starting treatment or increasing dose. They usually settle over a few weeks. The list below isn't exhaustive — see the full SmPC on eMC for complete information.
Common
- Nausea
- Diarrhoea
- Constipation
- Vomiting
- Decreased appetite
- Fatigue
Uncommon
- Dizziness
- Abdominal pain or discomfort
- Injection site reactions
- Hair loss
- Gallstones
- Hypoglycaemia (with type 2 diabetes)
Serious but rare
- Severe allergic reaction
- Acute pancreatitis (persistent severe stomach pain)
- Severe hypoglycaemia
- Severe gastrointestinal disease
- Diabetic retinopathy worsening
Report any side effect. If you experience a suspected side effect, tell your clinician and report it via the MHRA Yellow Card scheme. Yellow Card reporting helps the MHRA monitor the safety of all medicines.
Who can — and can't — take this.
Wegovy is a powerful, licensed medicine — and like any powerful medicine, it isn't right for everyone. Your clinician will assess your full history during consultation.
Wegovy may be suitable if you
- Are aged 18 or over
- Have a BMI of 30 or above (obesity)
- Have a BMI of 27–30 with a weight-related condition (e.g., type 2 diabetes, high blood pressure, sleep apnoea)
- Can safely self-administer a weekly subcutaneous injection
- Are committed to supporting your treatment with diet and activity changes
Wegovy is not suitable if you
- Are pregnant, planning pregnancy, or breastfeeding
- Have type 1 diabetes
- Have a personal or family history of medullary thyroid carcinoma or MEN2
- Have a history of pancreatitis
- Have severe gastrointestinal disease (e.g., gastroparesis)
- Have active eating disorders
- Have severe liver or kidney impairment (case-by-case review)
- Are allergic to semaglutide or any excipient
These lists aren't exhaustive — your clinician reviews your full medical history and current medicines before prescribing.
One monthly price. Clearly priced.
Your monthly price covers the medication, pen device and needles. A sharps bin, wipes and other items can be added at checkout — no subscription lock-ins and no hidden fees. Start at the lowest dose and escalate under clinical supervision.
* Standard monthly prices shown. New customers save £35 on their first order with code JUNE26 at checkout — so Wegovy starts from £80/mo. First order only; repeat orders are charged at the standard price.
Start with the eligibility check.
Free consultation. Reviewed by a UK-registered clinician. Refund in full if we decline treatment. No credit card required to start.